191 related articles for article (PubMed ID: 33333124)
21. Pbrm1 Steers Mesenchymal Stromal Cell Osteolineage Differentiation by Integrating PBAF-Dependent Chromatin Remodeling and BMP/TGF-β Signaling.
Sinha S; Biswas M; Chatterjee SS; Kumar S; Sengupta A
Cell Rep; 2020 Apr; 31(4):107570. PubMed ID: 32348751
[TBL] [Abstract][Full Text] [Related]
22. Targeting the vascular endothelial growth factor receptor-1 by the monoclonal antibody D16F7 to increase the activity of immune checkpoint inhibitors against cutaneous melanoma.
Lacal PM; Atzori MG; Ruffini F; Scimeca M; Bonanno E; Cicconi R; Mattei M; Bernardini R; D'Atri S; Tentori L; Graziani G
Pharmacol Res; 2020 Sep; 159():104957. PubMed ID: 32485280
[TBL] [Abstract][Full Text] [Related]
23. Blockade of CCR5 in melanoma: An alternative immune checkpoint modulator.
Escandon Brehm J; Bedogni B
Exp Dermatol; 2020 Feb; 29(2):196. PubMed ID: 31785018
[TBL] [Abstract][Full Text] [Related]
24. Arid2 regulates hematopoietic stem cell differentiation in normal hematopoiesis.
Bluemn T; Schmitz J; Chen Y; Zheng Y; Zhang Y; Zheng S; Burns R; DeJong J; Christiansen L; Izaguirre-Carbonell J; Wang D; Zhu N
Exp Hematol; 2021 Feb; 94():37-46. PubMed ID: 33346030
[TBL] [Abstract][Full Text] [Related]
25. PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8
Chen J; Song Y; Miao F; Chen G; Zhu Y; Wu N; Pang L; Chen Z; Chen X
Cancer Sci; 2021 Sep; 112(9):3437-3454. PubMed ID: 34152672
[TBL] [Abstract][Full Text] [Related]
26. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
27. Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma.
Nardin C; Laheurte C; Puzenat E; Boullerot L; Ramseyer M; Marguier A; Jacquin M; Godet Y; Aubin F; Adotevi O
J Invest Dermatol; 2022 Feb; 142(2):435-444. PubMed ID: 34352265
[TBL] [Abstract][Full Text] [Related]
28. Targeting signal-transducer-and-activator-of-transcription 3 sensitizes human cutaneous melanoma cells to BRAF inhibitor.
Wang X; Qu H; Dong Y; Wang G; Zhen Y; Zhang L
Cancer Biomark; 2018; 23(1):67-77. PubMed ID: 30010109
[TBL] [Abstract][Full Text] [Related]
29. Granzyme family acts as a predict biomarker in cutaneous melanoma and indicates more benefit from anti-PD-1 immunotherapy.
Wu X; Wang X; Zhao Y; Li K; Yu B; Zhang J
Int J Med Sci; 2021; 18(7):1657-1669. PubMed ID: 33746582
[TBL] [Abstract][Full Text] [Related]
30. Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.
Fukumoto T; Horita N
Eur J Cancer; 2021 Apr; 147():140-141. PubMed ID: 33662688
[No Abstract] [Full Text] [Related]
31. 9-Gene Signature Correlated With CD8
Yan K; Lu Y; Yan Z; Wang Y
Front Immunol; 2021; 12():622563. PubMed ID: 34220795
[TBL] [Abstract][Full Text] [Related]
32. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
33. Emerging PD-1/PD-L1 antagonists for the treatment of malignant melanoma.
Vanella V; Festino L; Vitale MG; Alfano B; Ascierto PA
Expert Opin Emerg Drugs; 2021 Jun; 26(2):79-92. PubMed ID: 33686894
[TBL] [Abstract][Full Text] [Related]
34. Role of immune checkpoint inhibitors in the revolutionization of advanced melanoma care.
Singh S; Numan A; Agrawal N; Tambuwala MM; Singh V; Kesharwani P
Int Immunopharmacol; 2020 Jun; 83():106417. PubMed ID: 32200155
[TBL] [Abstract][Full Text] [Related]
35. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Saito R; Sawada Y; Nakamura M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
[TBL] [Abstract][Full Text] [Related]
36. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
Front Immunol; 2021; 12():661737. PubMed ID: 34025662
[TBL] [Abstract][Full Text] [Related]
37. Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
Kim KB; Soroceanu L; de Semir D; Millis SZ; Ross J; Vosoughi E; Dar AA; Nosrati M; Desprez PY; Ice R; Chen M; Chetal K; Bhattacharjee A; Moretto J; Leong SP; Singer MI; Parrett BM; Minor DR; McAllister S; Miller JR; Salomonis N; Kashani-Sabet M
J Invest Dermatol; 2021 Aug; 141(8):2028-2036.e2. PubMed ID: 33610559
[TBL] [Abstract][Full Text] [Related]
38. Heterozygosity for ARID2 loss-of-function mutations in individuals with a Coffin-Siris syndrome-like phenotype.
Bramswig NC; Caluseriu O; Lüdecke HJ; Bolduc FV; Noel NC; Wieland T; Surowy HM; Christen HJ; Engels H; Strom TM; Wieczorek D
Hum Genet; 2017 Mar; 136(3):297-305. PubMed ID: 28124119
[TBL] [Abstract][Full Text] [Related]
39. SS18 together with animal-specific factors defines human BAF-type SWI/SNF complexes.
Middeljans E; Wan X; Jansen PW; Sharma V; Stunnenberg HG; Logie C
PLoS One; 2012; 7(3):e33834. PubMed ID: 22442726
[TBL] [Abstract][Full Text] [Related]
40. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.
Abou Alaiwi S; Nassar AH; Xie W; Bakouny Z; Berchuck JE; Braun DA; Baca SC; Nuzzo PV; Flippot R; Mouhieddine TH; Spurr LF; Li YY; Li T; Flaifel A; Steinharter JA; Margolis CA; Vokes NI; Du H; Shukla SA; Cherniack AD; Sonpavde G; Haddad RI; Awad MM; Giannakis M; Hodi FS; Liu XS; Signoretti S; Kadoch C; Freedman ML; Kwiatkowski DJ; Van Allen EM; Choueiri TK
Cancer Immunol Res; 2020 Aug; 8(8):1075-1084. PubMed ID: 32321774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]